TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 15:29:27 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

26 Apr 2024 15:05:17 By Nasdaq GlobeNewswire

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

04 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Tempest Reports Year End 2023 Financial Results and Provides Business Update

19 Mar 2024 15:25:36 By Nasdaq GlobeNewswire

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 15:15:51 By Nasdaq GlobeNewswire

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

08 Nov 2023 16:17:54 By Nasdaq GlobeNewswire

Tempest Adopts Limited Duration Stockholder Rights Plan

11 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

10 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 15:13:35 By Nasdaq GlobeNewswire

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

19 Jul 2023 07:00:01 By Nasdaq GlobeNewswire